+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Amicus Therapeutics Inc
  • Can-Fite BioPharma Ltd
  • Genentech Inc
  • Genzyme Corp
  • Greenovation Biotech GmbH
  • MORE
Protalix BioTherapeutics Inc (PLX): Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description: A detailed description of the company’s operations and business divisions.
  • Corporate strategy: Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis: A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history: Progression of key events associated with the company.
  • Major products and services: A list of major products, services and brands of the company.
  • Key competitors: A list of key competitors to the company.
  • Key employees: A list of the key executives of the company.
  • Executive biographies: A brief summary of the executives’ employment history.
  • Key operational heads: A list of personnel heading key departments/functions.
  • Important locations and subsidiaries: A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years: The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods: The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease; cystic fibrosis, inflammatory bowel diseases (IBD) and Gout. Protalix develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx protein expression system. Protalix is headquartered in Carmiel, Israel.

Protalix BioTherapeutics Inc Key Recent Developments

Mar 12,2020 Protalix BioTherapeutics reports fourth quarter and full year 2019 financial and business results
Dec 19,2019 Protalix BioTherapeutics adds two accomplished biopharmaceutical executives to its board of directors
Nov 07,2019 Protalix BioTherapeutics reports third quarter 2019 results and provides corporate update
Aug 22,2019 Protalix BioTherapeutics focuses on evaluating and pursuing alternatives to maximize shareholder value through refinancing & strategic partnerships

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Amicus Therapeutics Inc
  • Can-Fite BioPharma Ltd
  • Genentech Inc
  • Genzyme Corp
  • Greenovation Biotech GmbH
  • MORE
Section 1 - About the Company
  • Protalix BioTherapeutics Inc - Key Facts
  • Protalix BioTherapeutics Inc - Key Employees
  • Protalix BioTherapeutics Inc - Major Products and Services
  • Protalix BioTherapeutics Inc - History
  • Protalix BioTherapeutics Inc - Company Statement
  • Protalix BioTherapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Protalix BioTherapeutics Inc - Business Description
  • Protalix BioTherapeutics Inc - Corporate Strategy
  • Protalix BioTherapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Protalix BioTherapeutics Inc - Strengths
  • Protalix BioTherapeutics Inc - Weaknesses
  • Protalix BioTherapeutics Inc - Opportunities
  • Protalix BioTherapeutics Inc - Threats
  • Protalix BioTherapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Protalix BioTherapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Mar 12, 2020: Protalix BioTherapeutics reports fourth quarter and full year 2019 financial and business results
  • Dec 19, 2019: Protalix BioTherapeutics adds two accomplished biopharmaceutical executives to its board of directors
  • Nov 07, 2019: Protalix BioTherapeutics reports third quarter 2019 results and provides corporate update
  • Aug 22, 2019: Protalix BioTherapeutics focuses on evaluating and pursuing alternatives to maximize shareholder value through refinancing & strategic partnerships
  • Aug 13, 2019: Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics
  • Aug 08, 2019: Protalix BioTherapeutics reports second quarter 2019 results and provides corporate update
  • Jul 29, 2019: Protalix BioTherapeutics appoints Eyal Rubin as its new Senior Vice President and Chief Financial Officer
  • Jul 22, 2019: Protalix BioTherapeutics: Departure of Directors or certain officers; election of Directors; appointment of certain officers; compensatory arrangements of certain officers
  • May 21, 2019: Protalix BioTherapeutics appoints Dror Bashan as its New President and Chief Executive Officer and Director
  • May 06, 2019: Protalix Biotherapeutics reports 2019 first quarter results and provides corporate update
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Protalix BioTherapeutics Inc, Key Facts
  • Protalix BioTherapeutics Inc, Key Employees
  • Protalix BioTherapeutics Inc, Major Products and Services
  • Protalix BioTherapeutics Inc, History
  • Protalix BioTherapeutics Inc, Subsidiaries
  • Protalix BioTherapeutics Inc, Key Competitors
  • Protalix BioTherapeutics Inc, Ratios based on current share price
  • Protalix BioTherapeutics Inc, Annual Ratios
  • Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
  • Protalix BioTherapeutics Inc, Interim Ratios
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Protalix BioTherapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Protalix BioTherapeutics Inc, Performance Chart (2015 - 2019)
  • Protalix BioTherapeutics Inc, Ratio Charts
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Greenovation Biotech GmbH
  • Genentech Inc
  • Amicus Therapeutics Inc
  • iBio Inc
  • Genzyme Corp
  • AbbVie Inc
  • Can-Fite BioPharma Ltd
  • Medicago Inc
  • Shire LLC
Note: Product cover images may vary from those shown
Adroll
adroll